186 related articles for article (PubMed ID: 34626221)
1. Uterine cellular leiomyomas are characterized by common HMGA2 aberrations, followed by chromosome 1p deletion and MED12 mutation: morphological, molecular, and immunohistochemical study of 52 cases.
Dundr P; Gregová M; Hojný J; Krkavcová E; Michálková R; Němejcová K; Bártů M; Hájková N; Laco J; Mára M; Richtárová A; Zima T; Stružinská I
Virchows Arch; 2022 Feb; 480(2):281-291. PubMed ID: 34626221
[TBL] [Abstract][Full Text] [Related]
2. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
3. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
4. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
[TBL] [Abstract][Full Text] [Related]
5. IFITM1, CD10, SMA, and h-caldesmon as a helpful combination in differential diagnosis between endometrial stromal tumor and cellular leiomyoma.
Zhao W; Cui M; Zhang R; Shen X; Xiong X; Ji X; Tao L; Jia W; Pang L; Sun Z; Wang C; Zou H
BMC Cancer; 2021 Sep; 21(1):1047. PubMed ID: 34556086
[TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies.
Oliva E; Young RH; Amin MB; Clement PB
Am J Surg Pathol; 2002 Apr; 26(4):403-12. PubMed ID: 11914617
[TBL] [Abstract][Full Text] [Related]
7. MED12 is frequently mutated in ovarian and other adnexal leiomyomas.
Li Z; Maeda D; Kudo-Asabe Y; Tamura D; Nanjo H; Hayashi A; Ikemura M; Fukayama M; Goto A
Hum Pathol; 2018 Nov; 81():89-95. PubMed ID: 29944972
[TBL] [Abstract][Full Text] [Related]
8. 3'RNA and whole-genome sequencing of archival uterine leiomyomas reveal a tumor subtype with chromosomal rearrangements affecting either HMGA2, HMGA1, or PLAG1.
Jokinen V; Mehine M; Reinikka S; Khamaiseh S; Ahvenainen T; Äyräväinen A; Härkki P; Bützow R; Pasanen A; Vahteristo P
Genes Chromosomes Cancer; 2023 Jan; 62(1):27-38. PubMed ID: 35822448
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs involved in the HMGA2 deregulation and its co-occurrence with MED12 mutation in uterine leiomyoma.
Mello JBH; Barros-Filho MC; Abreu FB; Cirilo PDR; Domingues MAC; Pontes A; Rogatto SR
Mol Hum Reprod; 2018 Nov; 24(11):556-563. PubMed ID: 30376129
[TBL] [Abstract][Full Text] [Related]
10. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations.
Xie J; Ubango J; Ban Y; Chakravarti D; Kim JJ; Wei JJ
Genes Chromosomes Cancer; 2018 Oct; 57(10):485-494. PubMed ID: 29790226
[TBL] [Abstract][Full Text] [Related]
12. [Highly cellular leiomyoma of uterus: a comparative morphologic and immunohistochemical study of endometrial stromal tumors].
Liao X; Wang Y; Yue C; Liu Y; Wang H; Dai L; Hui Y
Zhonghua Bing Li Xue Za Zhi; 2002 Oct; 31(5):396-400. PubMed ID: 12485478
[TBL] [Abstract][Full Text] [Related]
13. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
Schwetye KE; Pfeifer JD; Duncavage EJ
Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
[TBL] [Abstract][Full Text] [Related]
14. MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.
Markowski DN; Bartnitzke S; Löning T; Drieschner N; Helmke BM; Bullerdiek J
Int J Cancer; 2012 Oct; 131(7):1528-36. PubMed ID: 22223266
[TBL] [Abstract][Full Text] [Related]
15. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers.
Mehine M; Kaasinen E; Heinonen HR; Mäkinen N; Kämpjärvi K; Sarvilinna N; Aavikko M; Vähärautio A; Pasanen A; Bützow R; Heikinheimo O; Sjöberg J; Pitkänen E; Vahteristo P; Aaltonen LA
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1315-20. PubMed ID: 26787895
[TBL] [Abstract][Full Text] [Related]
16. Histological and molecular analysis of cellular leiomyoma with sclerosis: linked to HMGA2 overexpression.
Griffin BB; Feng Y; Saini P; Lu X; Bulun S; Chakravarti D; Wei JJ
Histopathology; 2022 Nov; 81(5):587-599. PubMed ID: 35961656
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
[TBL] [Abstract][Full Text] [Related]
18. IFITM1 Outperforms CD10 in Differentiating Low-grade Endometrial Stromal Sarcomas From Smooth Muscle Neoplasms of the Uterus.
Busca A; Gulavita P; Parra-Herran C; Islam S
Int J Gynecol Pathol; 2018 Jul; 37(4):372-378. PubMed ID: 28700435
[TBL] [Abstract][Full Text] [Related]
19. [Myxoid mesenchymal tumors of uterus: endometrial stromal and smooth muscle tumors, myxoid variant].
Chesnais AL; Watkin E; Beurton D; Devouassoux-Shisheboran M
Ann Pathol; 2011 Jun; 31(3):152-8. PubMed ID: 21736994
[TBL] [Abstract][Full Text] [Related]
20. Genomics of uterine leiomyomas: insights from high-throughput sequencing.
Mehine M; Mäkinen N; Heinonen HR; Aaltonen LA; Vahteristo P
Fertil Steril; 2014 Sep; 102(3):621-9. PubMed ID: 25106763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
